Pharma market growth slowest since 1961: IMS Health

Share this article:

Last year, the US pharmaceuticals market grew at its slowest rate since 1961, research firm IMS Health said today.

According to the results of IMS' US Pharmaceutical Market Performance Review, sales in the US pharmaceuticals market were up just 3.8% in 2007, compared with growth of over 8% in 2006.

“The moderating growth trend that began in 2001 resumed last year following the one-time impact on market growth in 2006 from the implementation of Medicare Part D,” said Murray Aitken, IMS' SVP, healthcare insight, in a statement. “Last year, we saw a continuing shift away from primary care classes to biotech and specialist-driven therapies”

According to IMS, total US dispensed prescription volume grew at a 2.8% pace in 2007, compared with 4.6% in 2006. Antidepressants ranked as the leading therapy class by dispensed prescription volume in 2007. Rounding out the top five therapeutic categories were lipid regulators, codeine & combination pain medications, ace inhibitors and beta blockers.
 
IMS also forecasted that the introduction of new, novel biologics and vaccines, as well as the launch of five to eight new products with potential global blockbuster status in 2008 will help offset the impact of lower generics pricing. An additional $13 billion in branded products are likely to be exposed to generics this year, IMS said.

“The U.S. pharmaceutical market has entered a new era — one characterized by more modest growth due to the continuing impact of new generics products, fewer and more narrowly indicated novel medications, and closer scrutiny of safety issues,” added Aitken.  “We will see additional lower-cost treatment options for many patients, while new and innovative therapies are delivered to specific patient groups, such as those suffering with cancer.  Safety issues will be closely monitored and are likely to bring added caution to the market over the next several years.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...